

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income  
For the first quarter and period ended 31 March 2022  
(These figures have not been audited)

	Note	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
		Current quarter ended 31 March 2022 RM'000	Comparative quarter ended 31 March 2021 RM'000	Current year to date 31 March 2022 RM'000	Comparative year to date 31 March 2021 RM'000
(a) Revenue		3,907	1,097	3,907	1,097
(b) Cost of sales		(2,169)	(1,524)	(2,169)	(1,524)
(c) Gross profit/(loss)		1,738	(427)	1,738	(427)
(d) Other income		108	7	108	7
(e) Net gain arising from changes in fair value of biological assets		1,883	17	1,883	17
(f) Administrative expenses		(1,335)	(1,209)	(1,335)	(1,209)
(g) Finance costs		(14)	(18)	(14)	(18)
(h) Profit/(Loss) before tax		2,380	(1,630)	2,380	(1,630)
(i) Income tax expenses		(1)	(1)	(1)	(1)
(j) Profit/(Loss) for the period		2,379	(1,631)	2,379	(1,631)
(k) Other comprehensive income		-	-	-	-
(l) Total comprehensive profit/(loss) for the period		2,379	(1,631)	2,379	(1,631)
(m) Profit/(Loss) for the year attributable to:					
Equity holders of the parent		2,379	(1,631)	2,379	(1,631)
Non-controlling interest		-	-	-	-
		2,379	(1,631)	2,379	(1,631)
(n) Total comprehensive income/(loss) attributable to:					
Equity holders of the parent		2,379	(1,631)	2,379	(1,631)
Non-controlling interest		-	-	-	-
		2,379	(1,631)	2,379	(1,631)
(o) Basic earning per share (based on weighted average 71,789,377 ordinary shares) (sen)	26	3.31	(2.27)	3.31	(2.27)

(The Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2021 and the accompanying explanatory notes attached to the Interim Financial Statements)

Condensed Consolidated Statement of Financial Position (unaudited)  
As at 31 March 2022

	Unaudited As at end of Current Quarter 31 March 2022 RM'000	Audited As at preceding Financial Year Ended 31 December 2021 RM'000
<b>1 Non-current assets</b>		
Property, plant and equipment	257,242	257,029
Right of use assets	36	49
Investment in associates	17	17
Land held for development	858	858
	<u>258,153</u>	<u>257,953</u>
<b>2 Current Assets</b>		
Inventories	316	103
Biological assets	4,947	3,065
Receivables, deposits and prepayments	6,396	4,656
Tax recoverable	14	13
Cash and bank balances	1,568	1,291
	<u>13,241</u>	<u>9,128</u>
Assets classified as held for disposal	12,701	12,701
	<u>25,942</u>	<u>21,829</u>
<b>3 Total assets</b>	<u>284,095</u>	<u>279,782</u>
<b>EQUITY</b>		
<b>4 Capital and reserves attributable to equity holders of the Company</b>		
Share Capital	71,789	71,789
Revaluation and other reserves	135,214	135,214
Accumulated loss	(10,799)	(13,178)
<i>Equity attributable to equity holders of the parent</i>	<u>196,204</u>	<u>193,825</u>
Non-controlling interest	(12)	(12)
<b>Total equity</b>	<u>196,192</u>	<u>193,813</u>
<b>LIABILITIES</b>		
<b>5 Non current liabilities</b>		
Borrowings (interest bearing)	25,330	25,652
Lease liabilities	4	4
Deferred tax liabilities	35,532	35,532
	<u>60,866</u>	<u>61,188</u>
<b>6 Current Liabilities</b>		
Payables and accruals	23,505	21,030
Borrowings (interest bearing)	2,158	2,150
Lease liabilities	34	49
Bank overdraft	707	713
Tax liabilities	633	839
	<u>27,037</u>	<u>24,781</u>
<b>7 Total liabilities</b>	<u>87,903</u>	<u>85,969</u>
<b>8 Total equity and liabilities</b>	<u>284,095</u>	<u>279,782</u>
<b>9 Net assets per share (RM)</b>	2.73	2.70

(The Condensed Consolidated Statement of Financial Position should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2021 and the accompanying explanatory notes attached to the Interim Financial Statements)

Condensed Consolidated Statement of Changes In Equity (unaudited)  
For the period ended 31 March 2022

Group	Attributable to equity holders of the parent					
	Share Capital RM'000	Revaluation Reserves RM'000	(Accumulated loss)/ Retained Earnings RM'000	Total RM'000	Non- controlling Interests RM'000	Total Equity RM'000
At 1 January 2021	71,789	110,791	4,682	187,262	(9)	187,253
Other comprehensive income	-	-	-	-	-	-
Loss for the financial year	-	-	(1,631)	(1,631)	-	(1,631)
Total comprehensive loss for the period	-	-	(1,631)	(1,631)	-	(1,631)
At 31 March 2021	<u>71,789</u>	<u>110,791</u>	<u>3,051</u>	<u>185,631</u>	<u>(9)</u>	<u>185,622</u>
At 1 January 2022	71,789	135,214	(13,178)	193,825	(12)	193,813
Other comprehensive income	-	-	-	-	-	-
Profit for the financial year	-	-	2,379	2,379	-	2,379
Total comprehensive income for the period	-	-	2,379	2,379	-	2,379
At 31 March 2022	<u>71,789</u>	<u>135,214</u>	<u>(10,799)</u>	<u>196,204</u>	<u>(12)</u>	<u>196,192</u>

(The Condensed Consolidated Statement of changes in equity should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2021 and the accompanying explanatory notes attached to the Interim Financial Statements)

**MENTIGA CORPORATION BERHAD**  
**Company No. 197001001000 (10289-K)**

**Condensed Consolidated Statement of Cash Flows**  
**For the financial period ended 31 March 2022**  
(These figures have not been audited)

	Cumulative Quarter	
	Current year to date 31 March 2022	Comparative year to date 31 March 2021
	RM'000	RM'000
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Profit/(Loss) before tax	2,380	(1,630)
Adjustments for :		
Depreciation of property, plant and equipment	1,111	748
Depreciation of right-of-use assets	13	13
Fair value movement in biological asset	(1,882)	(16)
Interest expense	14	18
Operating profit/(loss) before working capital changes	1,636	(867)
Changes in working capital		
-inventories	(213)	60
-receivables, deposits and prepayment	(1,740)	17
-payables	2,475	574
Cash flow from/(used in) operations	2,158	(216)
Interest paid	(14)	(18)
Tax paid	(207)	(207)
Net cash flow (used in)/from operating activities	1,936	(440)
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Property, plant and equipment		
- Acquisition	(86)	-
- Plantation expenditure	(1,382)	(632)
Net cash flow used in investing activities	(1,469)	(632)
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Repayment of borrowings	(295)	-
Proceed from term loan	144	-
Repayment of hire purchase creditors	(20)	(9)
Repayment of lease liabilities	(14)	(13)
Net cash flow used in financing activities	(185)	(22)
<b>Net decrease in Cash &amp; Cash Equivalents</b>	283	(1,095)
<b>Cash &amp; Cash Equivalents as at 1 January</b>	578	1,352
<b>Cash &amp; Cash Equivalents at end of period</b>	861	257
<b>Cash and cash equivalents at end of year comprised:</b>		
Cash and bank balances	1,568	1,246
Bank overdraft (secured)	(707)	(989)
	861	257

(The Condensed Consolidated Statement of Cash Flows should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2021 and the accompanying explanatory notes attached to the Interim Financial Statements)